FIELD: biotechnologies.
SUBSTANCE: peptide derivatives of exendin -3 (1-39) are described, having activity of glucagon-like peptides (GLP-1), modified near C-end with amine and capable of binding with their N-end to GLP-1-receptors. Application of peptide derivatives of exendin-3 is disclosed for production of an agent for diagnostics and therapy of diseases, where expression of GLP-1 receptors is important, to define density of insulin-producing cells in a tissue, in order to define expression of GLP-1 -receptors or their density.
EFFECT: invention may be used to produce an agent for diagnostics and therapy of diseases, where expression of GLP-1 receptors is important.
21 cl
| Title | Year | Author | Number |
|---|---|---|---|
| INVENTION REFERRED TO GLP- AND EXENDINAM | 2010 |
|
RU2486197C2 |
| PEPTIDE EXENDIN-4 DERIVATIVES | 2005 |
|
RU2420536C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| RADIOACTIVE METAL-LABELLED ANTI-CADHERIN ANTIBODY | 2011 |
|
RU2577125C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| PHARMACEUTICAL COMPOSITION FOR NON-ALCOHOLIC FATTY LIVER DISEASE PREVENTION OR TREATMENT | 2013 |
|
RU2635966C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
| BOMBESIN ANALOGUE PEPTIDE ANTAGONIST CONJUGATES | 2009 |
|
RU2523531C2 |
| SOMATOSTATINE PEPTIDES | 1996 |
|
RU2160741C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
